Six companies representing a combined 35% of the Freedom Portfolio released earnings last week. Here is a quick look at their performance since the beginning of last week:

• Shopify (SHOP) – Up 12.9%
• Mercado Libre (MELI) – Up 12.9%
• Redfin (RDFN) – Up 24.3%
• Roku (ROKU) – Up 1.0%
• Shockwave Medical (SWAV) – Down 2.4%
• CRISPR Therapeutics (CRSP) – Up 4.8%

I already briefly touched on the earnings from the two biggest positions: Shopify and Mercado Libre, but I wanted to speak briefly on the others as well:

Redfin – The biggest move belongs to Redfin, and it feels like the market is finally catching on to how well the company has been performing over the past two quarters. The stock is up nearly 50% this year alone. I liked almost everything about their earnings report, but there are two things I want to keep an eye on. The first is that stock based compensation doesn’t get out of hand. The second is that they continue to take market share. I was hoping at some point to see an acceleration of gains in market share at some point but it continues to disappointingly move in fits and starts, although the general trend is upward.

Roku – Roku also had a pretty good quarter, but I think this was a case where a lot of the good news was already priced in (the stock has quintupled over the past 2 and a half years). So while it was disappointing to not see a bigger move, it’s understandable. I want to try to do some more research into the connected TV space over the coming months, as I have a lot of exposure to companies like The Trade Desk (TTD), Telaria (TLRA), and Roku and I don’t feel like I understand that space as well as I should.

Shockwave Medical and CRISPR Therapeutics – The main thing to say about these two companies is that there’s honestly not much to say about them in terms of their earnings reports. Both are such early stage companies that it’s fairly meaningless to look at things like revenue and earnings. I’m less concerned if they met some analyst estimates and far more interested in learning more about how clinical trials and adoption rates are coming. In both cases, I remain cautiously optimistic (with the huge caveat that I am not a doctor by any stretch) and so am happy holding both as small positions for now.